Printer Friendly

miRNA Tools and Services Market to Reach USD 620m by 2022, Research and Markets Forecasts.

M2 PHARMA-May 5, 2017-miRNA Tools and Services Market to Reach USD 620m by 2022, Research and Markets Forecasts

(C)2017 M2 COMMUNICATIONS

- The global miRNA tools and services market was valued at USD 146m in 2015 and is expected to reach USD 620m by 2022, growing at a CAGR of 23.4% during the forecast period, according to a new report from Dublin-based Research and Markets.

It is expected to witness significant growth owing to the rise in incidence of cancer, auto-immune, and cardiovascular diseases.

In addition, miRNA molecules possess specific properties, such as higher tissue and organ specificity; and ability to cross the blood-brain barrier easily, that make them a favorable option to be used as biomarkers for a range of neurological diseases, thereby driving the market growth.

However, quantification challenges and development of in-use techniques, such as microarray, hamper the market growth.

The global miRNA tools and services market is segmented on the basis of product, technique, end user, and geography. The miRNA tools and services market is bifurcated into research tools and services. Research tools market is further divided into reagents, kits, and consumables.

On the other hand, the services market is classified into miRNA extraction services, quantification services, microarray services, sequencing services, functional studies services, and others.

Based on techniques, the market is segmented into extraction tools, qRT-PCR, NGS, microarray, functional analysis tools (such as miRNA mimetics, inhibitors, and target site blockers), and others (such as labeling, ISH, and northern blotting tools).

Key players in this market include Qiagen, Thermo Fisher Scientific Inc., Illumina, Inc., Agilent Technologies, GE Healthcare Dharmacon Inc., GeneCopoeia, Inc., Promega Corp., Bio-Rad Laboratories, Inc., Merck and Co., Inc. and New England Biolabs.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:May 5, 2017
Words:291
Previous Article:Vertex Grants USD 1m to 15 Non-profit Organizations; Will Fund Initiatives for People Living with Cystic Fibrosis.
Next Article:Ignyta Prices 12.5m Shares of Common Stock.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters